Abstract
Background: The superiority of dabigatran has been well proven in the standard dosing regimen in prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF) and extended venous thromboembolism (VTE) treatment. Dabigatran, an anticoagulant with a good safety profile, reduces intracranial bleeding in patients with atrial fibrillation and decreases major and clinically relevant non-major bleeding in acute VTE treatment. However, several important clinical issues are not fully covered by currently available directions with regard to dabigatran administration. The prominent one is reflected in the fact that dynamic impairment in renal function due to dehydratation may lead to haemorragic complications on the one hand, while on the other hand glomerular hyperfiltration may be a possible cause of dabigatran subdosing, hence reducing the drug’s efficacy. Furthermore, limitations of the Cockcroft-Gault formula, considered a standard equation for assessing the renal function, may imply that other calculations are likely to obtain more accurate estimates of the kidney function in specific patient populations.
Method and Conclusions: Although not routinely recommended, a possibility of monitoring dabigatran in special clinical settings adds to optimization of its dosage regimens, timely perioperative care and administration of urgently demanded thrombolytic therapy, therefore significantly improving this drug’s safety profile. Despite the fact that dabigatran has fewer reported interactions with drugs, food constituents, and dietary supplements, certain interactions still remain, requiring considerable caution, notably in elderly, high bleeding risk patients, patients with decreased renal function and those on complex drug regimens. Additionally, upon approval of idarucizumab, an antidote to dabigatran solution, hitherto being a major safety concern, has been finally reached, which plays a vital role in life-threatening bleeding and emergency interventions and surgery.Keywords: Dabigatran, pharmacokinetics, pharmacodynamics, dose optimization, interactions, metabolism, comorbidities.
Graphical Abstract
Current Drug Metabolism
Title:Dabigatran - Metabolism, Pharmacologic Properties and Drug Interactions
Volume: 18 Issue: 7
Author(s): Nebojsa M. Antonijevic*, Ivana D. Zivkovic, Ljubica M. Jovanovic, Dragan M. Matic, Mladen J. Kocica, Igor B. Mrdovic, Vladimir I. Kanjuh and Milica D. Culafic
Affiliation:
- Clinic of Cardiology, Clinical Center of Serbia, Belgrade,Serbia
Keywords: Dabigatran, pharmacokinetics, pharmacodynamics, dose optimization, interactions, metabolism, comorbidities.
Abstract: Background: The superiority of dabigatran has been well proven in the standard dosing regimen in prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF) and extended venous thromboembolism (VTE) treatment. Dabigatran, an anticoagulant with a good safety profile, reduces intracranial bleeding in patients with atrial fibrillation and decreases major and clinically relevant non-major bleeding in acute VTE treatment. However, several important clinical issues are not fully covered by currently available directions with regard to dabigatran administration. The prominent one is reflected in the fact that dynamic impairment in renal function due to dehydratation may lead to haemorragic complications on the one hand, while on the other hand glomerular hyperfiltration may be a possible cause of dabigatran subdosing, hence reducing the drug’s efficacy. Furthermore, limitations of the Cockcroft-Gault formula, considered a standard equation for assessing the renal function, may imply that other calculations are likely to obtain more accurate estimates of the kidney function in specific patient populations.
Method and Conclusions: Although not routinely recommended, a possibility of monitoring dabigatran in special clinical settings adds to optimization of its dosage regimens, timely perioperative care and administration of urgently demanded thrombolytic therapy, therefore significantly improving this drug’s safety profile. Despite the fact that dabigatran has fewer reported interactions with drugs, food constituents, and dietary supplements, certain interactions still remain, requiring considerable caution, notably in elderly, high bleeding risk patients, patients with decreased renal function and those on complex drug regimens. Additionally, upon approval of idarucizumab, an antidote to dabigatran solution, hitherto being a major safety concern, has been finally reached, which plays a vital role in life-threatening bleeding and emergency interventions and surgery.Export Options
About this article
Cite this article as:
Antonijevic M. Nebojsa*, Zivkovic D. Ivana , Jovanovic M. Ljubica, Matic M. Dragan , Kocica J. Mladen , Mrdovic B. Igor , Kanjuh I. Vladimir and Culafic D. Milica , Dabigatran - Metabolism, Pharmacologic Properties and Drug Interactions, Current Drug Metabolism 2017; 18 (7) . https://dx.doi.org/10.2174/1389200218666170427113504
DOI https://dx.doi.org/10.2174/1389200218666170427113504 |
Print ISSN 1389-2002 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5453 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Safety and Efficacy of Intra-arterial Tirofiban Injection During Mechanical Thrombectomy for Large Artery Occlusion
Current Neurovascular Research Editorial (Hot Topic: The New Kids on the Block: Oral Direct IIa and Xa Inhibitors Enter the Proscenium of Anticoagulation Treatment)
Current Clinical Pharmacology The Blood Brain Barrier, Mechanisms of Cerebral Edema, and the Use of Anti-Inflammatory and other Anti-Edema Agents in Neuro-Oncology
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Anabolic Androgenic Steroid (AAS) Related Deaths: Autoptic, Histopathological and Toxicological Findings
Current Neuropharmacology Platelets and Vascular Risk: An Option for Treatment
Current Pharmaceutical Design Diffuse Alveolar Hemorrhage, A Potentially Life-Threatening Manifestation in Systemic Lupus Erythematosus and the Antiphospholipid Syndrome
Current Respiratory Medicine Reviews Recent Advancement in the Treatment of Cardiovascular Diseases: Conventional Therapy to Nanotechnology
Current Pharmaceutical Design Effects and Perspectives of Chinese Patent Medicines for Tonifying <i>Qi</i> and Promoting Blood Circulation on Patients with Cerebral Infarction
Current Vascular Pharmacology Primary Antiphospholipid Syndrome and Pulmonary Hypertension
Current Pharmaceutical Design Targeting the Arrhythmogenic Substrate in Atrial Fibrillation: Focus on Structural Remodeling
Current Drug Targets Iatrogenic Right Atrial Thrombus Complicated by Pulmonary Embolism: Management and Outcomes
Current Cardiology Reviews Therapeutic Hypothermia in Brain Injuries and Related Diseases
Recent Patents on Inflammation & Allergy Drug Discovery The Vasculature as a Target in the Treatment of Pulmonary Emphysema
Current Drug Targets Current Therapeutic Strategies and Future Perspectives for the Treatment of Venous Thromboembolism
Current Pharmaceutical Design Drug-Related Cardiotoxicity for the Treatment of Haematological Malignancies in Elderly
Current Pharmaceutical Design Editorial [Hot topic: Antithrombotic Therapy in Cardiovascular and Haematological Diseases: New Perspectives (Executive Editors: Sergio Siragusa, Giuseppe Barbaro and Giovanni Fazio)]
Current Pharmaceutical Design Lifelong Endocrine Fluctuations and Related Cognitive Disorders
Current Pharmaceutical Design Low Molecular Weight Heparins and Glomerular Filtration Rate: A Report to be Considered
Current Vascular Pharmacology Emerging Anticoagulants
Current Medicinal Chemistry Integrin Function and Signaling as Pharmacological Targets in Cardiovascular Diseases and in Cancer
Current Pharmaceutical Design